Redx Pharma Plc

Full interview: Redx Pharma gets green light to increase dose in lead cancer drug trial

Redx Pharma PLC (LON:REDX) CEO Lisa Anson spoke to Proactive London's Andrew Scott following the news they've been given the go-ahead to up the dose of its lead cancer drug.

It comes after the firm successfully navigated the first part of its early-stage trial for RXC004.

The asset's part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors. 

Quick facts: Redx Pharma Plc

Price: £0.09

Market: AIM
Market Cap: £11.1 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...



Redx Pharma's Lisa Anson discusses potential US$203mln cancer deal

Redx Pharma PLC's (LON:REDX) Lisa Anson speaks to Proactive London's Andrew Scott after announcing they've sold one of their cancer research programmes for up to US$203mln. The agreement with Jazz Pharmaceuticals (NASDAQ:JAZZ) has a tiered payment structure and will see Redx receive a...

on 10/7/19

2 min read